Which is the best botulinum toxin brand in the world?

There is no universally superior botulinum toxin brand: the clinical literature consistently demonstrates that onabotulinumtoxinA (Botox/Vistabel, Allergan/AbbVie), abobotulinumtoxinA (Dysport/Azzalure, Ipsen), incobotulinumtoxinA (Xeomin/Bocouture, Merz), prabotulinumtoxinA (Jeuveau, Evolus) and daxibotulinumtoxinA formulations each achieve comparable safety and efficacy profiles when dosed correctly for their respective unit conventions — which are not interchangeable. The question "which is best" therefore reduces to a more precise set of sub-questions: best for which indication, which anatomical zone, which patient profile, and in whose hands?

The global dominance of Botox is largely a function of market history. Allergan received the first FDA approval for glabellar lines in 2002, building a decade-long head start in physician training and patient recognition. That commercial primacy does not translate to pharmacological superiority. What the approved labelling does establish, for every one of these products, is that the dose scales are not convertible between them. The FDA label for Jeuveau states that "Units of biological activity of JEUVEAU cannot be converted into Units of any other botulinum toxin". The Xeomin label states that its units "cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method". The European summary of product characteristics for Nuceiva states that "botulinum toxin units are not interchangeable from one product to another. Doses recommended are different from other botulinum toxin preparations". No conversion ratio between brands is published on this page for that reason: a fixed conversion ratio is a clinical rule of thumb, not a labelled equivalence, and the manufacturer's own labelling for Dysport cautions that the ratio used in the past may be inadequate. Comparability between correctly dosed products is the position stated in the opening paragraph above; what no label supports is a factor that would let anyone translate one brand's dose into another's.

What does differ meaningfully between formulations:

• Diffusion radius — abobotulinumtoxinA (Dysport) diffuses somewhat more broadly than onabotulinumtoxinA at equivalent clinical doses; this can be an advantage in large muscle fields (frontalis, platysma) and a limitation in precision zones (periorbital).
• Complexing proteins — incobotulinumtoxinA (Xeomin) is purified beyond the toxin complex. Its own label describes the step: "the active ingredient is separated from the proteins (hemagglutinins and non-hemagglutinins) through a series of steps yielding the active neurotoxin with molecular weight of 150 kDa, without accessory proteins". That is a documented fact of composition, and this page states nothing beyond it: the label makes no claim that the absence of accessory proteins reduces antibody formation, prolongs duration or prevents resistance. The approved labels in this class document that antibodies may form, and the mitigation the labels describe is a lower dose at a longer interval — not a change of brand.
• Onset speed — abobotulinumtoxinA tends to show earlier visible onset (2–5 days) in a subset of patients, though individual variation is substantial.
• Storage — incobotulinumtoxinA does not require refrigeration before reconstitution, offering logistical advantages in some clinical settings.

In summary: brand selection is a clinical tool, not a ranking. An experienced injector matches formulation to indication, dosing to anatomy, and adjusts based on individual response over successive sessions.

There is no credible top-10 ranking of botox brands: the botulinum toxin brand names below differ by molecule, manufacturer, unit scale and approved indication — not by the quality of result they can deliver.

Botulinum toxin brand names in the main regulated markets, with the molecule, the manufacturer and what the approved labelling documents. Sources: each product's own approved labelling (US FDA and EMA) and the manufacturers' product information.

Read the last column across the five rows and the pattern is hard to miss: what separates the brands is unit scale, composition and the indication each was approved for — not the quality of result achievable with them. That is why nothing on this page is ranked by brand. The ranking that is clinically useful is a ranking by indication: which formulation suits a large muscle field, which suits a precision zone near the eye, which suits a patient with a documented reaction history. Two further consequences follow from the table. First, a list of brand names runs longer than a list of molecules, because the same product is approved under different names in different markets — Jeuveau and Nuceiva being the clearest case. Second, no row can be read across into another: the units are not a common currency.

Independence. Dr. Thiago Perfeito holds no commercial relationship, sponsorship or consultancy agreement with any of the manufacturers named on this page. He purchases and administers the toxins used at INTI — Botox, Dysport and Xeomin — in clinical practice, and the comparison above reflects approved labelling and public regulatory records rather than any commercial arrangement.

Clinical outcome in botulinum toxin treatment is determined primarily by injector expertise, anatomical knowledge and dosing precision, not by brand selection among the approved products. The approved labels declare that potency units are specific to each preparation and cannot be converted into the units of any other, so dose is decided product by product rather than read across brands.

This is not a diplomatic hedge. It reflects a structural reality: the approved brands are all manufactured under stringent pharmaceutical controls; they all contain botulinum toxin type A; they are all safe when administered by a trained physician at recommended doses; and they all lose efficacy predictably over the same 3–6 month window. The marginal difference between a correctly dosed Botox and a correctly dosed Dysport in the glabella of the same patient is smaller than the difference between an undertreated glabella and a correctly treated one — regardless of brand.

For patients coming from clinics in Manhattan, Mayfair, Zurich or Singapore, the relevant questions to ask any physician in Brasília are not "which brand do you use?" but rather:

• Do you perform a full facial analysis before choosing dose and injection points?
• Do you adjust the unit convention for the specific formulation you are using?
• Do you document injection maps for continuity of care across sessions?
• Is the product sourced through official distributor channels with verified cold-chain integrity?

Regarding Korean toxins specifically: the question of whether they are "inferior" conflates manufacturing origin with regulatory rigour. Korean pharmaceutical manufacturing — particularly companies subject to MFDS oversight and multinational regulatory submissions — operates to standards comparable to European and North American facilities. Korean-manufactured toxins hold United States approval, each under its own US trade name: the product made at Daewoong, approved in 2019 as JEUVEAU (Evolus) and authorised in the European Union as NUCEIVA, and Hugel's letibotulinumtoxinA, approved in 2024 as LETYBO. The more relevant question is whether the specific product has been approved by the relevant authority for the market in which it is being used. That determination is regulatory, not geographic.

One clinical note worth flagging for patients who report rapid loss of effect: the most common cause is undertreated dose, not antibody formation. Neutralising antibodies do occur but are uncommon in standard cosmetic dosing regimens. A patient whose Botox "stopped working" after two years is far more likely to have experienced progressively conservative dosing than true immunological resistance.

Related reading:
Where to get the best Botox in Brasília
Dr. Thiago Perfeito
Procedures

Updated 5 June 2026